当前位置： SCI文献检索 > JOURNAL OF NEUROSURGERY期刊下所有文献 > Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.

Abstract：

OBJECTIVE:The object of this retrospective study was to investigate the impact of targeted therapies on overall survival (OS), distant intracranial failure, local failure, and radiation necrosis among patients treated with radiation therapy for renal cell carcinoma (RCC) metastases to the brain. METHODS:All patients diagnosed with RCC brain metastasis (BM) between 1998 and 2015 at a single institution were included in this study. The primary outcome was OS, and secondary outcomes included local failure, distant intracranial failure, and radiation necrosis. The timing of targeted therapies was recorded. Multivariate Cox proportional-hazards regression was used to model OS, while multivariate competing-risks regression was used to model local failure, distant intracranial failure, and radiation necrosis, with death as a competing risk. RESULTS:Three hundred seventy-six patients presented with 912 RCC BMs. Median OS was 9.7 months. Consistent with the previously validated diagnosis-specific graded prognostic assessment (DS-GPA) for RCC BM, Karnofsky Performance Status (KPS) and number of BMs were the only factors prognostic for OS. One hundred forty-seven patients (39%) received vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Median OS was significantly greater among patients receiving TKIs (16.8 vs 7.3 months, p < 0.001). Following multivariate analysis, KPS, number of metastases, and TKI use remained significantly associated with OS.The crude incidence of local failure was 14.9%, with a 12-month cumulative incidence of 13.4%. TKIs did not significantly decrease the 12-month cumulative incidence of local failure (11.4% vs 14.5%, p = 0.11). Following multivariate analysis, age, number of BMs, and lesion size remained associated with local failure. The 12-month cumulative incidence of radiation necrosis was 8.0%. Use of TKIs within 30 days of SRS was associated with a significantly increased 12-month cumulative incidence of radiation necrosis (10.9% vs 6.4%, p = 0.04). CONCLUSIONS:Use of targeted therapies in patients with RCC BM treated with intracranial SRS was associated with improved OS. However, the use of TKIs within 30 days of SRS increases the rate of radiation necrosis without improving local control or reducing distant intracranial failure. Prospective studies are warranted to determine the optimal timing to reduce the rate of necrosis without detracting from survival.

journal_name

J Neurosurg

journal_title

Journal of neurosurgery

authors

Juloori A,Miller JA,Parsai S,Kotecha R,Ahluwalia MS,Mohammadi AM,Murphy ES,Suh JH,Barnett GH,Yu JS,Vogelbaum MA,Rini B,Garcia J,Stevens GH,Angelov L,Chao ST

doi

10.3171/2018.8.JNS182100

subject

Has Abstract

pub_date

2019-01-18 00:00:00

pages

1-9

eissn

0022-3085

issn

1933-0693

pii

2018.8.JNS182100

pub_type

杂志文章

在线工具

Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.